



Financial Reporting Manager

Kala is an emerging pharmaceutical company on the verge of commercialization. We are seeking a Financial Reporting Manager with extensive SEC reporting experience. This is an opportunity for the right individual to join Kala at a very exciting time. Come join an experienced and highly motivated team!

Key Responsibilities for this role will include:

- Manage all aspects of our external SEC documents, including the 10K, 10Q, 8K and other ad hoc filings
- Partner with the VP and Controller to lead Sarbanes-Oxley compliance effort
- Coordinate the review of filings with external auditors, legal counsel, accounting staff and executive management
- Research accounting literature and apply technical US GAAP standards to complex business issues
- Lead implementation efforts and ongoing monitoring of significant new pronouncements, including ongoing communication and education of financial management on pronouncements
- With support from the accounting department, and coordinate the quarterly review and annual audit process with our external auditors

Our ideal candidate will have:

- Bachelor/Masters degree in Accounting
- 5-7 years related experience
- Public accounting experience required with public company clients – straight from public or mix of public/industry
- Big 4 experience strongly preferred
- CPA required
- Excellent Communication Skills (Written & Verbal)
- Possess technical expertise related to GAAP and external reporting including SEC reporting, stock option accounting, revenue recognition, acquisitions, and Sarbanes-Oxley requirements
- Demonstrated recent experience in researching and preparing technical accounting memorandums for complex issues and new pronouncements
- Understanding of accounting processes, procedure and internal controls
- Ability to adapt quickly and learn new tasks independently
- Ability to manage competing priorities with deadlines
- Pharmaceutical or Life Science company experience

About Us:

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™(KPI-121 1%) for the treatment of inflammation and

pain following ocular surgery, for which we have submitted a NDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease, which is currently in Phase 3 clinical development.